Eli Lilly and [LLY] vs Amgen [AMGN] Detailed Stock Comparison
Eli Lilly and
NYSE
Loading...
Amgen
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Eli Lilly and wins in 9 metrics, Amgen wins in 11 metrics, with 0 ties. Amgen appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Eli Lilly and | Amgen | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 49.28 | 22.62 | Amgen |
| Price-to-Book Ratio | 37.07 | 20.03 | Amgen |
| Debt-to-Equity Ratio | 217.89 | 756.65 | Eli Lilly and |
| PEG Ratio | 0.54 | 0.25 | Amgen |
| EV/EBITDA | 28.85 | 12.20 | Amgen |
| Profit Margin (TTM) | 25.91% | 18.96% | Eli Lilly and |
| Operating Margin (TTM) | 45.81% | 32.73% | Eli Lilly and |
| EBITDA Margin (TTM) | 45.81% | 32.73% | Eli Lilly and |
| Return on Equity | 86.29% | 99.14% | Amgen |
| Return on Assets (TTM) | 16.55% | 7.51% | Eli Lilly and |
| Free Cash Flow (TTM) | $414.30M | $10.39B | Amgen |
| Dividend Yield | 0.52% | 4.09% | Amgen |
| 1-Year Return | -18.22% | -16.83% | Amgen |
| Price-to-Sales Ratio (TTM) | 12.72 | 4.26 | Amgen |
| Enterprise Value | $714.65B | $196.97B | Eli Lilly and |
| EV/Revenue Ratio | 13.42 | 5.64 | Amgen |
| Gross Profit Margin (TTM) | 84.27% | 67.20% | Eli Lilly and |
| Revenue per Share (TTM) | $59 | $65 | Amgen |
| Earnings per Share (Diluted) | $15.33 | $12.22 | Eli Lilly and |
| Beta (Stock Volatility) | 0.47 | 0.48 | Eli Lilly and |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Eli Lilly and vs Amgen Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Eli Lilly and | -0.12% | 3.88% | 18.13% | -6.98% | -8.09% | -2.91% |
| Amgen | -2.24% | -2.56% | -3.01% | -7.03% | -11.56% | 6.60% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Eli Lilly and | -18.22% | 144.55% | 389.97% | 753.64% | 2,010.62% | 1,268.46% |
| Amgen | -16.83% | 19.62% | 11.61% | 83.60% | 400.71% | 225.82% |
News Based Sentiment: Eli Lilly and vs Amgen
Eli Lilly and
News based Sentiment: POSITIVE
Eli Lilly delivered a strong Q2 2025, raised its guidance, and made significant progress in its pipeline across multiple therapeutic areas, including oncology and Alzheimer's. The launch of an AI-powered drug discovery platform further strengthens its long-term growth prospects, despite competition in the weight-loss market.
Amgen
News based Sentiment: POSITIVE
Amgen demonstrated a strong financial performance in Q2 2025, exceeding earnings and revenue expectations. Coupled with positive clinical trial data and expanded FDA approval for Repatha, the company appears well-positioned for continued growth, despite mixed analyst sentiment and varied institutional investor activity.
Performance & Financial Health Analysis: Eli Lilly and vs Amgen
| Metric | LLY | AMGN |
|---|---|---|
| Market Information | ||
| Market Cap | $691.79B | $148.80B |
| Market Cap Category | Mega cap | Large cap |
| 10 Day Avg. Volume | 2,877,030 | 2,148,930 |
| 90 Day Avg. Volume | 5,555,130 | 2,112,570 |
| Last Close | $755.39 | $276.39 |
| 52 Week Range | $623.78 - $942.35 | $253.30 - $339.17 |
| % from 52W High | -19.84% | -18.51% |
| All-Time High | $972.53 (Aug 19, 2024) | $346.85 (Jul 22, 2024) |
| % from All-Time High | -22.33% | -20.31% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.38% | 0.09% |
| Quarterly Earnings Growth | 0.91% | 0.92% |
| Financial Health | ||
| Profit Margin (TTM) | 0.26% | 0.19% |
| Operating Margin (TTM) | 0.46% | 0.33% |
| Return on Equity (TTM) | 0.86% | 0.99% |
| Debt to Equity (MRQ) | 217.89 | 756.65 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $20.38 | $13.80 |
| Cash per Share (MRQ) | $3.95 | $14.91 |
| Operating Cash Flow (TTM) | $10.94B | $12.01B |
| Levered Free Cash Flow (TTM) | $-2,265,437,440 | $10.42B |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.52% | 4.09% |
| Last 12-Month Dividend | $4.10 | $11.64 |
Valuation & Enterprise Metrics Analysis: Eli Lilly and vs Amgen
| Metric | LLY | AMGN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 49.28 | 22.62 |
| Forward P/E | 33.34 | 13.37 |
| PEG Ratio | 0.54 | 0.25 |
| Price to Sales (TTM) | 12.72 | 4.26 |
| Price to Book (MRQ) | 37.07 | 20.03 |
| Market Capitalization | ||
| Market Capitalization | $691.79B | $148.80B |
| Enterprise Value | $714.65B | $196.97B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 13.42 | 5.64 |
| Enterprise to EBITDA | 28.85 | 12.20 |
| Risk & Other Metrics | ||
| Beta | 0.47 | 0.48 |
| Book Value per Share (MRQ) | $20.38 | $13.80 |
Financial Statements Comparison: Eli Lilly and vs Amgen
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | LLY | AMGN |
|---|---|---|
| Revenue/Sales | $12.73B | $8.15B |
| Cost of Goods Sold | $2.22B | $2.97B |
| Gross Profit | $10.50B | $5.18B |
| Research & Development | $2.73B | $1.49B |
| Operating Income (EBIT) | $5.41B | $1.18B |
| EBITDA | $5.92B | $4.08B |
| Pre-Tax Income | $3.46B | $1.97B |
| Income Tax | $696.80M | $243.00M |
| Net Income (Profit) | $2.76B | $1.73B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | LLY | AMGN |
|---|---|---|
| Cash & Equivalents | $3.09B | $8.81B |
| Total Current Assets | $41.26B | $26.93B |
| Total Current Liabilities | $30.07B | $23.01B |
| Long-Term Debt | $34.50B | $54.01B |
| Total Shareholders Equity | $15.85B | $6.21B |
| Retained Earnings | $15.10B | $-27.14B |
| Property, Plant & Equipment | N/A | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | LLY | AMGN |
|---|---|---|
| Operating Cash Flow | $4.88B | $1.71B |
| Capital Expenditures | $-1.51B | $-411.00M |
| Free Cash Flow | $-1.60B | $980.00M |
| Debt Repayment | N/A | $-2.50B |
| Common Stock Repurchase | $-1.20B | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | LLY | AMGN |
|---|---|---|
| Shares Short | 8.04M | 11.80M |
| Short Ratio | 1.22 | 5.85 |
| Short % of Float | 0.01% | 0.02% |
| Average Daily Volume (10 Day) | 2,877,030 | 2,148,930 |
| Average Daily Volume (90 Day) | 5,555,130 | 2,112,570 |
| Shares Outstanding | 897.54M | 537.00M |
| Float Shares | 895.44M | 536.99M |
| % Held by Insiders | 0.00% | 0.00% |
| % Held by Institutions | 0.84% | 0.84% |
Dividend Analysis & Yield Comparison: Eli Lilly and vs Amgen
| Metric | LLY | AMGN |
|---|---|---|
| Last 12-Month Dividend | $4.10 | $11.64 |
| Last 12-Month Dividend Yield | 0.52% | 4.09% |
| 3-Year Avg Annual Dividend | $4.02 | $9.51 |
| 3-Year Avg Dividend Yield | 0.22% | 0.80% |
| 3-Year Total Dividends | $12.05 | $28.54 |
| Ex-Dividend Date | Feb 14, 2025 | Aug 22, 2025 |